June 6, 2025
rose-b-avatar-teal
Disability in Health Care Reporting Fellow

Some friends and I discussed V.S. Ramachandran’s famous "mirror box" therapy over drinks last night, which has long been one of my favorite experiments. It alleviates phantom limb pain, using only a mirror. Then, when I got home from the bar, I saw a study showing that mice can recognize an artificial limb as its own, too.

Embodiment is so…bizarre. 

QUID PRO QUO

Republicans dangle pay raise to physicians — if they stay quiet on Medicaid cuts

ALEX WROBLEWSKI/AFP via Getty Images

Lawmakers have begun lobbying the lobbyists: asking health care interests to keep quiet — or speak up — about potential cuts to Medicaid, which will put 10.9 million people at risk of losing health insurance. 

Republicans have urged doctor groups to hold back on criticisms of the cuts, pointing out the inclusion of an enticing carrot for doctors groups in President Trump's tax bill: Pay increases for physicians from Medicare. Increasing the amount that Medicare pays doctors — especially over the long-term, tied to inflation — has been a top priority for physicians groups in Washington for years. Conversely, Democrats are asking lobbyists to put Republicans on blast for how these cuts would affect providers and patients, but the party lacks leverage as Republicans can pass the measure without Democratic lawmakers. STAT’s Daniel Payne has the scoop

As Congress bats around ideas for slashing Medicaid spending, more than half of Americans are fretting that the reductions would impair their family’s ability to obtain and afford health care, according to a new poll from KFF Health Tracking Poll. The fear extends to Republican voters, too, including 76% of MAGA supporters and other Republican Medicaid enrollees.


POLICY

NIH, FDA diverge on AI strategy

It looks like the NIH is thinking about AI differently than the FDA, who earlier this week released a “rushed” AI tool across the agency. At the Coalition for Health AI summit at Stanford University yesterday, NIH principal deputy director Matthew Memoli announced a request for public input on the agency’s AI strategy. The NIH, he said, sees AI as being an integral part of scientific research going forward — especially as datasets for research swell in size. The request seeks suggestions on how the NIH can use AI to make its functions more useful and how it can foster trust and transparency in using and evaluating AI tools for applications ranging from clinical AI tools to peer review.

The agency plans to name a new chief AI officer as well — STAT noticed yesterday that the NIH’s inaugural chief AI officer, Gil Alterovitz, has already stepped down and returned to the Veterans Health Agency, where he is also chief AI officer, according to his LinkedIn. It’s a bit surprising that the NIH made such an announcement at an event for the health AI nonprofit, as four House Republicans last year sent letters to federal officials criticizing the government’s relationship to CHAI, resulting in Biden officials stepping down from the CHAI board. – Brittany Trang

(If you like this type of content about AI, you should subscribe to Brittany’s newsletter.)


EUGENICS

Move over, Francis Galton

Americans’ self-reported race is a poor proxy for their genetic ancestry, according to a large government study published Thursday that could have major implications for how health disparities are researched.

Writing in the American Journal of Human Genetics, researchers analyzed the genomes of more than 200,000 participants in the All of Us cohort, which was established by the National Institutes of Health to create a dataset that accurately represented the makeup of the United States. The study arrives amid a heated debate over the role racial categories play in research as the Trump administration has targeted grants it deems related to “diversity, equity, and inclusion” as being “unscientific.” 

“The clear message here is that these are two distinct constructs, they mean different things, and they should not be used interchangeably,” said Luisa Borrell, a social epidemiologist at the CUNY School of Public Health. STAT’s Anil Oza dives deep into the study and the fraught history between geneticists and the idea of race.



SIDE EFFECTS

GLP-1 drugs linked to elevated risk of eye disease

People with diabetes taking GLP-1 drugs had a low but elevated risk of an age-related eye disease that can sometimes lead to blindness, a new observational study concludes.

The research, published Thursday in JAMA Ophthalmology, found that after one year, more than twice as many people on GLP-1 drugs developed neovascular age-related macular degeneration compared to similar people who were not taking the drugs. The risk was 0.2% in people taking GLP-1s and 0.1% in those who didn’t. 

Famous for their success in helping people lose weight, GLP-1 drugs were originally intended to control their blood sugar. But as their use has exploded, various eye problems have been reported, including abnormal blood vessel growth. STAT’s Elizabeth Cooney has more about these powerful medications and their possible side effects.   


FOUNTAIN OF YOUTH

Sadly, Red Bull does not give you wings

To the dismay of line cooks and bodybuilders everywhere, a new report found that taurine — an amino acid abundant in plants, animals and energy drinks — was found to be an unreliable biomarker for aging.

Taurine has long been a darling of longevity seekers, but results published Thursday have cast doubt on a 2023 study that made the amino acid a staple ingredient for biohackers searching for anti-aging elements (a la tech mogul Bryan Johnson). The new study data showed that taurine rises with age, pulling data from 32 monkeys, 39 mice, one cohort of 742 humans, one cohort of 159 humans, and another cohort of 72 humans.

The data are a reminder of just how messy and complicated longevity studies can be, and how elusive treatments, or even just reliable markers, for aging remain. STAT’s Jason Mast has the study's full readout.


FIRST OPINION

At-home sexual assault kits come with legal, health risks

The Food and Drug Administration recently approved the first at-home cervical cancer screening test in May, marking a significant shift toward accessible, patient-driven health care. But the agency’s decision may revive the debate over at-home sexual assault kits, at a time when states and companies selling these kits are battling over their legality, writes Rachell Ekroos, a forensic nursing expert.

The concept of at-home sexual assault evidence collection kits emerged in the late 2010s at the height of the “Me Too” movement, when companies began offering them as a way to empower survivors to collect forensic evidence privately and on their own terms. But a legal fight over their accuracy soon emerged, and advocacy groups worried about the lack of oversight, quality control, and linkage to support options for the survivor. To understand why Ekroos is worried that the newly approved at-home cervical screening tests will revive the movement for at-home sexual assault kits, read on.


More around STAT